Navigation Links
Subcutaneous administration of an antiemetic for treating vomiting caused by chemotherapy
Date:11/16/2007

The subcutaneous administration of granisetron, an antiemetic pharmaceutical drug (suitable for control of vomiting), achieves similar blood concentrations to those administered intravenously. This was the conclusion of clinical tests undertaken by specialists at the University Hospital of Navarra, the results of which have been recently published in the prestigious North American medical journal, The Oncologist.

Granisetrn is a pharmaceutical drug the efficacy of which against vomiting (antiemetic), when administered orally or intravenously, has already been shown, but never studied when given subcutaneously. The research shows that the antiemetic granisetron, administered subcutaneously, behaves in a similar manner as when injected intravenously. The advantage of the subcutaneous method is the ease of treatment for non-hospitalised patients. For these patients using the intravenous method it is problematic, requiring, as it does, specialised care; while administering orally may involve the patient vomiting.

Home use and emergencies

This is why subcutaneous administration opens new perspectives, providing a comfortable and easy way of home-based treatment, either with self-medication by the patients themselves or administered by their carers, in either case reducing the dependence on trained medical personnel.

The fundamental objective of the work undertaken was, thereby, to demonstrate if it were feasible for the patients themselves to manage to self-medicate the antiemetic in their own homes in case of vomiting as a consequence of chemotherapy treatment. In this way, the patient does not have to go to a hospital in order to control nauseas and vomiting. Nevertheless, this form of medication is also useful for healthcare personnel such as the emergency services.

Trials

A total of 30 patients participated in the trial. All were medicated with granisetron, using one of the two forms of administration, intravenous or subcutaneous, during the first cycle of chemotherapy and, in the following cycle, the other alternative was employed. Then a number of blood samples of all the patients were obtained in order to determine the concentration of the pharmaceutical drug in each sample.

The conclusions of the study confirm that the concentrations of granisetron obtained were equivalent in both methods of medication. This is why the research supports the administration of granisetron subcutaneously as a new alternative for the treatment of cancer patients.


'/>"/>

Contact: Egoitz Etxebeste
egoitz@elhuyar.com
Elhuyar Fundazioa
Source:Eurekalert

Related medicine news :

1. VNUS Medical Technologies Announces Resignation of Chief Financial Officer and VP, Finance & Administration
2. Office of Administration Announces Plan to Preserve Health Care Benefits for Current, Future Retired Commonwealth Employees
3. Wells Fargo Offers Online Benefit Administration for Business and Individual Healthcare Consumers
4. Administration Anesthetized to Ailments of Nations Children
5. Supratek Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SP1049C for the treatment of metastatic adenocarcinoma of the upper gastrointestinal tract
6. Siemens Medical Solutions Receives CCHIT Certification for Soarian Clinicals With Siemens Pharmacy and Med Administration Check
7. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia
8. Abbott Receives U.S. Food and Drug Administration Approval for New Lower-Strength Kaletra(R) (lopinavir/ritonavir) Tablet for Pediatric HIV Patients
9. Chip PC Wins Europes Largest Thin Client Tender to Supply 20,000 Thin Clients and Management Software to German RZF - Financial Administration of North Rhine-Westphalia County
10. ActiPatch(TM) Granted Market Clearance by the Food & Drug Administration in the Kingdom of Jordan
11. ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... payment industry today announced its strategic partnership with Connance, a healthcare industry ... The two companies’ proven, proprietary technology combine to provide health systems, hospitals ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
Breaking Medicine Technology: